Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TMPRSS15 | P98073 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948334 | 0.91 | TMPRSS15 (0.45) | SMN1; SMN2TMPRSS15ALDH1A1HTTL3MBTL1 | |
| SCHEMBL14821119 | 0.91 | SMN1; SMN2 (0.46) | SMN1; SMN2RECQLTMPRSS15ALDH1A1HTT | |
| SCHEMBL14821498 | 0.89 | TMPRSS15 (0.44) | SMN1; SMN2TMPRSS15ALDH1A1HTTL3MBTL1 | |
| SCHEMBL15946453 | 0.89 | TMPRSS15 (0.44) | SMN1; SMN2RECQLTMPRSS15 | |
| SCHEMBL15948350 | 0.88 | TMPRSS15 (0.43) | TMPRSS15ALDH1A1L3MBTL1POLB | |
| SCHEMBL15948348 | 0.85 | CA2 (0.41) | SMN1; SMN2TMPRSS15ALDH1A1HTTL3MBTL1 | |
| SCHEMBL14821494 | 0.85 | TMPRSS15 (0.44) | TMPRSS15 | |
| SCHEMBL14821495 | 0.83 | TMPRSS15 (0.42) | TMPRSS15 | |
| SCHEMBL14821499 | 0.83 | TMPRSS15 (0.45) | SMN1; SMN2TMPRSS15ALDH1A1HTTL3MBTL1 | |
| SCHEMBL47281 | 0.82 | TMPRSS15 (0.43) | SMN1; SMN2RECQLTMPRSS15ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013041204-A1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | 2LUTION GmbH (DE) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | SMN1; SMN2 4324/4885RECQL 3713/4885TMPRSS15 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.